Hadassah

Thrombotech Receives Regulatory Approval for Stroke Medicine Trials in the US

Wednesday, Mar 28 2012

Thrombotech Ltd., a biotechnology company based on cutting-edge stroke research at the Hadassah University Medical Center, has received approval from the United States' Food and Drug Administration (FDA) to expand clinical trials to the US for its lead product, THR-18. This medicine is designed to improve the safety and efficacy of tPA, the currently available treatment for ischemic stroke.

THR-18 is designed to allow tPA to dissolve blood clots easily, extending its short therapeutic time window and diminishing life-threatening side effects. It is currently undergoing Phase IIA clinical trials at several hospitals in Israel, including Hadassah, and is awaiting regulatory approvals in Europe and India.

"This important regulatory approval serves as external validation for our development program and the quality of the science and management behind the company," says Thrombotech Chief Executive Officer Dr. Ruth Ben Yakar. "It will enable us to recruit more patients in some of the leading medical centers specializing in stroke in the US and move towards commercialization of the therapy for this serious medical condition."

Hadasit, Hadassah's technology transfer company, holds a 24% stake in Thrombotech. Commenting on the approval, Ophir Shahaf, Chief Executive Officer of Hadasit Bio-Holdings, Hadasit's publicly traded subsidiary, stated: "We are proud to expand the clinical trial to medical centers in the US, a world leader in Central Nervous System therapeutics and stroke treatment in particular."

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Jul 11 2018

Improving Kidney Health of Premature Babies

Is the TV hit show Grey's Anatomy taking its inspiration from Hadassah Hospital? After all, cast members did visit Hadassah Ein Kerem in 2011. Dr. Oded Volovelsky, Head of Hadassah's new Pediatric Nephrology Unit says, only half-jokingly, that TV doc Meredith Grey might have read his research.

READ MORE ›
alt_text

Wednesday, Jul 11 2018

Hadassah Cancer Specialists Explore Link Between Colorectal Cancer and BRCA Mutations

Looking further into the link between colorectal cancer and BRCA 1 and 2 genetic mutations, researchers from the Hadassah Medical Center’s Sharett Institute of Oncology, together with colleagues from Chaim Sheba Medical Center, analyzed data from 32 patients with lower gastrointestinal cancers.

READ MORE ›
alt_text

Monday, Jul 9 2018

World Hepatitis Day: Hadassah’s Contribution to the Global Battle Against this Disease

“Hadassah Medical Organization's (HMO) greatest contribution to the global battle against Hepatitis are the vaccines that have been developed here,” said Prof. Daniel Shouval, as we mark World Hepatitis Day on July 28.

READ MORE ›
alt_text

Tuesday, Jul 3 2018

Prioritizing Treatment Options in Breast Cancer

When a patient with metastatic breast cancer fails to respond to conventional treatment and gene analysis identifies several targetable molecular mutations, how do you prioritize treatment options?

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More